Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agnes Hong

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Patient Preference and Adherence|May 15, 2025
Patients' Preferences for Attributes of Oral vs Injectable Androgen Deprivation Therapy in Prostate Cancer: A Discrete Choice ExperimentSean P Collins, Agnes Hong, Brett Hauber, et al.
The Journal of Urology|February 15, 2023
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate CancerUmang Swami, Agnes Hong, Nader N El-Chaar, et al.
European Urology Open Science|February 1, 2024
Implications of Delayed Testosterone Recovery in Patients with Prostate CancerMark A Preston, Agnes Hong, Robert Dufour, et al.
Research Square|November 1, 2024
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancerNadine Friedrich, Nadine Friedrich, Jessica Janes, et al.
Urologic Oncology|July 13, 2024
Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancerMark A Preston, Ramin Ebrahimi, Agnes Hong, et al.
Prostate Cancer and Prostatic Diseases|March 28, 2024
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerDaniel J George, Krishnan Ramaswamy, Hongbo Yang, et al.
Prostate Cancer and Prostatic Diseases|July 4, 2025
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancerNadine A Friedrich, Jessica L Janes, Joshua Parrish, et al.
JAMA Network Open|December 9, 2024
Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate CancerNeeraj Agarwal, Daniel J George, Zachary Klaassen, et al.
Prostate Cancer and Prostatic Diseases|July 24, 2025
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancerStephen J Freedland, Agnes Hong, Nader El-Chaar, et al.
Prostate Cancer and Prostatic Diseases|April 2, 2024
Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancerDaniel J George, Neeraj Agarwal, Krishnan Ramaswamy, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Patient Preference and Adherence|May 15, 2025
Patients' Preferences for Attributes of Oral vs Injectable Androgen Deprivation Therapy in Prostate Cancer: A Discrete Choice ExperimentSean P Collins, Agnes Hong, Brett Hauber, et al.
The Journal of Urology|February 15, 2023
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate CancerUmang Swami, Agnes Hong, Nader N El-Chaar, et al.
European Urology Open Science|February 1, 2024
Implications of Delayed Testosterone Recovery in Patients with Prostate CancerMark A Preston, Agnes Hong, Robert Dufour, et al.
Research Square|November 1, 2024
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancerNadine Friedrich, Nadine Friedrich, Jessica Janes, et al.
Urologic Oncology|July 13, 2024
Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancerMark A Preston, Ramin Ebrahimi, Agnes Hong, et al.
Prostate Cancer and Prostatic Diseases|March 28, 2024
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerDaniel J George, Krishnan Ramaswamy, Hongbo Yang, et al.
Prostate Cancer and Prostatic Diseases|July 4, 2025
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancerNadine A Friedrich, Jessica L Janes, Joshua Parrish, et al.
JAMA Network Open|December 9, 2024
Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate CancerNeeraj Agarwal, Daniel J George, Zachary Klaassen, et al.
Prostate Cancer and Prostatic Diseases|July 24, 2025
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancerStephen J Freedland, Agnes Hong, Nader El-Chaar, et al.
Prostate Cancer and Prostatic Diseases|April 2, 2024
Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancerDaniel J George, Neeraj Agarwal, Krishnan Ramaswamy, et al.
Pageof 3